Denali Therapeutics Inc. - COMMON STOCK (DNLI) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2017 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
DNLI on Nasdaq
Shares outstanding
147,179,178
Price per share
$16.51
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
135,496,666
Total reported value
$1,967,413,087
% of total 13F portfolios
0.01%
Share change
-2,221,408
Value change
-$29,612,927
Number of holders
235
Price from insider filings
$16.51
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Denali Therapeutics Inc. - COMMON STOCK (DNLI) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 7.2% $173,095,065 10,490,610 BlackRock, Inc. 31 Mar 2025
FMR LLC 5.8% $123,948,417 8,536,392 FMR LLC 30 Sep 2025
WELLINGTON MANAGEMENT GROUP LLP 3.9% $82,251,923 5,664,733 Wellington Management Group LLP 30 Jun 2025
Capital Research Global Investors 3.8% $90,373,982 5,477,211 Capital Research Global Investors 31 Dec 2024
BAILLIE GIFFORD & CO 5.6% -23% $31,927,897 -$7,858,384 2,198,891 -20% BAILLIE GIFFORD & CO 30 Jun 2025

As of 30 Sep 2025, 235 institutional investors reported holding 135,496,666 shares of Denali Therapeutics Inc. - COMMON STOCK (DNLI). This represents 92% of the company’s total 147,179,178 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) together control 74% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 8.4% 12,289,626 +2% 0% $178,445,369
VANGUARD GROUP INC 8.1% 11,992,918 +1.5% 0% $174,137,169
BAILLIE GIFFORD & CO 7.9% 11,591,585 -3% 0.12% $168,309,813
FMR LLC 4.3% 6,340,316 -16% 0% $92,061,393
T. Rowe Price Investment Management, Inc. 3.8% 5,638,567 +74% 0.05% $81,872,000
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC 3.7% 5,465,037 -13% 0.02% $79,352,339
STATE STREET CORP 3.7% 5,464,261 +21% 0% $79,341,070
Temasek Holdings (Private) Ltd 3.6% 5,355,832 0% 0.27% $77,766,681
Capital Research Global Investors 3.2% 4,760,858 +0.22% 0.01% $69,127,658
PRICE T ROWE ASSOCIATES INC /MD/ 3.1% 4,568,368 -31% 0.01% $66,333,000
BAKER BROS. ADVISORS LP 2.5% 3,731,695 0% 0.39% $54,184,211
ALLIANCEBERNSTEIN L.P. 2.4% 3,520,414 +12% 0.02% $51,116,411
GEODE CAPITAL MANAGEMENT, LLC 2.4% 3,466,057 +9.3% 0% $50,335,167
Crestline Management, LP 2.3% 3,410,732 -12% 85% $49,523,829
Holocene Advisors, LP 2.1% 3,135,712 +678% 0.1% $45,530,538
Point72 Asset Management, L.P. 1.7% 2,519,535 +14% 0.08% $36,583,650
DIMENSIONAL FUND ADVISORS LP 1.6% 2,357,214 -2.3% 0.01% $34,226,491
GOLDMAN SACHS GROUP INC 1.5% 2,163,705 +16% 0% $31,416,997
UBS Group AG 1.4% 2,012,353 +112% 0.01% $29,219,365
STEMPOINT CAPITAL LP 1.2% 1,734,659 +145% 5.1% $25,187,249
MORGAN STANLEY 1.1% 1,689,492 +29% 0% $24,531,439
Fisher Asset Management, LLC 1.1% 1,631,496 +7.6% 0.01% $23,689,321
MILLENNIUM MANAGEMENT LLC 0.89% 1,307,171 +45% 0.01% $18,980,123
PRINCIPAL FINANCIAL GROUP INC 0.86% 1,271,190 +18% 0.01% $18,457,679
NORTHERN TRUST CORP 0.84% 1,234,179 +2.7% 0% $17,920,279

Institutional Holders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 2,675,442 $44,171,785 +$17,587,932 $16.51 20
2025 Q3 135,496,666 $1,967,413,087 -$29,612,927 $14.52 235
2025 Q2 137,594,175 $1,925,023,022 +$63,128,608 $13.99 228
2025 Q1 132,874,634 $1,807,534,753 +$50,388,875 $13.60 219
2024 Q4 127,929,251 $2,607,162,085 +$11,750,487 $20.38 222
2024 Q3 126,754,706 $3,691,746,017 +$83,332,107 $29.13 215
2024 Q2 123,900,320 $2,876,933,310 +$81,781,105 $23.22 202
2024 Q1 122,410,671 $2,512,114,129 +$149,691,318 $20.52 208
2023 Q4 115,037,875 $2,465,293,115 +$48,272,802 $21.46 208
2023 Q3 108,753,813 $2,243,639,062 +$15,314,130 $20.63 194
2023 Q2 107,385,972 $3,168,950,262 +$5,897,175 $29.51 198
2023 Q1 108,017,472 $2,487,976,875 +$45,585,839 $23.04 198
2022 Q4 106,059,670 $2,949,511,974 +$353,989,026 $27.81 195
2022 Q3 92,590,614 $2,841,171,715 -$31,157,203 $30.69 192
2022 Q2 92,689,565 $2,727,755,557 +$180,988,868 $29.43 177
2022 Q1 86,720,578 $2,790,606,045 +$40,452,227 $32.17 177
2021 Q4 85,268,721 $3,803,185,901 +$18,535,233 $44.60 204
2021 Q3 82,102,816 $4,142,844,228 +$169,589,833 $50.45 205
2021 Q2 77,780,665 $6,099,806,785 +$34,022,640 $78.44 204
2021 Q1 77,751,278 $4,438,997,286 +$78,721,718 $57.10 213
2020 Q4 66,445,136 $5,564,771,315 +$193,800,989 $83.76 199
2020 Q3 82,769,611 $2,965,793,194 +$14,445,549 $35.83 168
2020 Q2 82,768,394 $2,001,309,869 +$63,425,607 $24.18 142
2020 Q1 80,458,775 $1,408,929,438 +$149,773,734 $17.51 127
2019 Q4 70,860,285 $1,234,391,510 -$9,532,468 $17.42 107
2019 Q3 71,458,501 $1,094,801,327 -$4,573,862 $15.32 112
2019 Q2 63,549,412 $1,319,252,281 +$54,502,235 $20.76 113
2019 Q1 61,057,319 $1,417,761,132 +$44,297,416 $23.22 113
2018 Q4 68,108,281 $1,407,070,297 -$256,309 $20.66 89
2018 Q3 58,053,077 $1,262,045,654 +$108,737,022 $21.74 76
2018 Q2 53,287,730 $812,631,603 +$13,608,742 $15.25 65
2018 Q1 60,832,830 $1,196,651,992 +$60,152,032 $19.69 56
2017 Q4 58,144,510 $909,309,000 +$907,640,000 $15.64 45